Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford and Cornell University, is partnering with infectious disease modellers and public health experts from over 40 countries in Africa, Asia and America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.

The COVID-19 International Modelling Consortium (CoMo Consortium)

COVID-19 is continuing to spread across the world at a rapid rate. By 30 April 2020, the pandemic had affected at least 185 countries/regions, with more than 4 million confirmed cases and in excess of 200,000 deaths globally. The pandemic has presented a myriad of challenges for health care systems around the world, including pressures on health care staff, general hospital beds, intensive care capacity and specialized equipment. In addition to the health effects of the disease, lockdown measures to contain the disease have placed a significant economic burden on countries and communities. Policymakers must balance curtailing the negative health effects of the pandemic against minimizing the economic impact on societies, calibrating these decisions for the epidemiological, social, cultural and infrastructure context of an individual country. There is currently no treatment or vaccine for COVID-19, so countries that choose to try to interrupt its spread must rely on non-pharmaceutical interventions (NPIs); these NPIs fall into various categories of behaviour change, including self-isolation for symptomatic individuals, increased hand hygiene, and physical distancing in social settings.

The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford together with academic colleagues at Cornell University and is partnering with infectious disease modellers and other public health experts from more than 40 countries across Africa, Asia, and South and North America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.

The CoMo Consortium has developed an age-structured, compartmental SEIR (susceptible-exposed-infectious-recovered) model to estimate the trajectory of COVID-19 based on different scenarios and to assess the potential impact of the various NPIs, as well as treatments and vaccines, when they become available. A user-friendly, web-based interface enables training on and use of the model by member modelling groups, while dashboards and visualization tools allow policymakers to see the predicted impacts of different NPIs in real time. The CoMo Consortium comprises several working groups, with each group playing a specific role, as outlined below.

CoMo Consortium working groups

  • Policy support. Facilitating a direct link between the modellers (from multiple countries) involved in developing the models and interpreting their outputs, the in-country experts and the policymakers in each country.
  • Model development. Writing, coding, debugging and updating the primary model structure.
  • Interface development. Creating a web-based interface that enables non-modellers to run the models, based on their local parameters.
  • Economic modelling. Conducting modelling to assess the economic costs and impacts arising from an intervention or a suite of interventions.
  • Evidence synthesis. Combining scientific evidence relating to the COVID-19 pandemic with model projections, economics and financing to create evidence-based policy briefs.
  • Outreach and communications. Engaging both in-country experts and policymakers who are seeking additional modelling support to deal with their specific COVID-19 situation.

CoMo Consortium model outputs

A diagram of the baseline model structure, including both age-structured epidemiological and health care utilization components

A diagram of the baseline model structure, including both age-structured epidemiological and health care utilization components

The predictions of the model can enable policymakers to make data-based decisions to inform their public health responses, such as:

  • The impact of the various mitigation strategies on virus transmission, mechanisms for ‘flattening he epidemic curve’, lockdown release strategies, and deciding which interventions will be most effective in their specific context.
  • The comparative demand for general hospital beds and ICU beds under different intervention strategies.
  • The quantity of tests, personal protective equipment, ventilators and other supportive tools needed for the diagnosis and treatment of patients with COVID-19, and the costs of the equipment needed.

Graphics

 

Examples of graphs showing the predicted effects of different combinations of non-pharmaceutical interventions

The CoMo Consortium model is currently being used around the world to facilitate policy discussions and shape intervention strategies. It is also being modified for local purposes by the in-country teams and being used as a comparator with existing in-country models.

Please see the CoMo Consortium PDF for further details.

- Thank you Rima Shretta for this text and images

What is mathematical modeling and how can it help control the COVID-19 pandemic?
Video produced by
WHO Eastern Mediterranean Region

 

Similar stories

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

@Oxford Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford MORU Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

UK National Health Service begins rollout of Oxford coronavirus vaccine

@Oxford General

The first patients are being vaccinated as part of the UK’s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, at the Oxford University NHS Hospitals Trust. The Oxford AstraZeneca vaccinations will be delivered at a small number of hospitals for the first few days for surveillance purposes, as is standard practice, before the bulk of supplies are sent to hundreds of GP-led services later in the week.

Receiving and responding to community feedback during health system crises in Kenya

KWTRP Publication Research

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

Susie Dunachie awarded flagship NIHR career development award

@Oxford Awards & Appointments

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.